SCHEMBL13434849

SCHEMBL13434849

CC(C)Oc1cc(F)ccc1Nc1ncnc2ccsc12

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MKNK2 Q9HBH9 19/20 0.53
MKNK1 Q9BUB5 15/20 0.52
EIF4E P06730 4/20 0.52
AURKA O14965 1/20 0.45
TEK Q02763 1/20 0.45
AURKB Q96GD4 1/20 0.45
EGFR P00533 1/20 0.45
ERBB2 P04626 1/20 0.45
PIM1 P11309 1/20 0.45
BRAF P15056 1/20 0.45
PIM3 Q86V86 1/20 0.45
PIM2 Q9P1W9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13434851 0.87 DYRK1A (0.55) MKNK2MKNK1EIF4EAURKATEK
SCHEMBL13434854 0.85 EGFR (0.47) MKNK2MKNK1EIF4EAURKATEK
SCHEMBL13434879 0.83 MKNK2 (0.56) MKNK2MKNK1EIF4E
SCHEMBL13434841 0.82 MKNK2 (0.57) MKNK2MKNK1EIF4EEGFRERBB2
SCHEMBL3798841 0.82 MEN1 (0.58) MKNK2MKNK1EIF4E
SCHEMBL13434861 0.80 MKNK2 (0.53) MKNK2MKNK1EIF4EEGFRERBB2
SCHEMBL15428429 0.80 MKNK2 (0.49) MKNK2MKNK1EIF4EAURKATEK
SCHEMBL15428428 0.79 MKNK2 (0.63) MKNK2MKNK1EIF4EAURKATEK
SCHEMBL13434847 0.79 MKNK2 (0.54) MKNK2MKNK1EIF4EAURKATEK
SCHEMBL20576064 0.77 MKNK2 (0.53) MKNK2MKNK1EIF4EEGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633201-B2 Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-21 US disclosed
US-8633201-B2 Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-21 US disclosed
EP-2004656-B1 THIENOPYRIMIDINES HAVING MNK1 /MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INT (DE) 2013-07-10 EP disclosed
US-20100056548-A1 THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-03-04 US disclosed
US-20100056548-A1 THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-03-04 US disclosed
WO-2007115822-A1 THIENOPYRIMIDINES HAVING MNKL /MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056548-A1 THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS CMPK1, DTYMK, NEK9 MKNK2 8/4885MKNK1 29/4885EIF4E 2334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.